📰 Genentech News
Page 147 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
June 9, 2023
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly
June 9, 2023
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5... | June 9, 2023
June 9, 2023
- The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors
June 9, 2023
CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.Investigators reported no disease progression or deaths among individuals who achieved a complete response (CR) to the chimeric antigen receptor T-cell therapy, according to a
June 9, 2023
CHICAGO — The addition of atezolizumab to cabozantinib failed to improve clinical outcomes for patients with metastatic renal cell carcinoma who experienced progression on or after immune checkpoint inhibitor therapy, study results showed.Subgroup analysis of the randomized phase 3 CONTACT-03 trial, presented at ASCO Annual Meeting, did not identify any subset of patients who may benefit
June 9, 2023
Peli BioThermal, the life science industry’s partner from discovery to distribution, has opened its newest full-service network station in Valencia, Calif.
June 9, 2023
Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.
June 9, 2023
Pharmacogenomics Market Trends and Insights By Technology (Microarray, Sequencing, and Polymerase Chain Reaction), By Application (Oncology, Cardiology,...
June 9, 2023
If the government can set price controls for essential medicines without allowing for judicial review, the government can do the same for other essential industries.
June 8, 2023
First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).